



SISTHAEMA

HEVO
T



TODAY YOU ENTER THE NEW ERA OF DERMAL REGENERATION



SISTHAEMA HEVO *T* is the final result of a thorough analysis of scientific developments and the application of sophisticated and patented production technologies.

SISTHAEMA HEVO *T* innovative & exclusive science-based concept relies on:

- Trehalose & Hyaluronic Acid Synergy
- Selective Spectrum Technology
- Fragments of Hyaluronic Acid





TREHALOSE & HYALURONIC ACID SYNERGY

- The combination of **Trehalose** and **Hyaluronic Acid** exerts an intense and prolonged dermal regeneration;
- Trehalose stabilizes Hyaluronic Acid in SISTHAEMA HEVO *T* bonding to its chains and protecting it from enzymatic degradation and oxidation;
- Trehalose is a disaccharide obtained through condensation of two glucose molecules.

The combination of Hyaluronic Acid and Trehalose operates in a highly synergic manner, allowing a strong and intensive action incomparably superior to the one exerted by Hyaluronic Acid alone.

AN EXCLUSIVE
SYNERGY,
INNOVATIVE
& PATENTED



SELECTIVE SPECTRUM TECHNOLOGY

SELECTIVE SPECTRUM TECHNOLOGY

The Selective Spectrum Technology (SST) is an advanced procedure exclusively applied by SISTHAEMA HEVOT.

- This unique technology allows to highlight a spectrum of different Hyaluronic Acid molecular weights, instead of a specific one;
- Spectrums are “sets” of various molecular weights with different spatial arrangements;
- SST enables us to select the most suitable spectrum for the therapeutic target.

HYALURONANS 2.0

FRAGMENTS OF HYALURONIC ACID



The fragmentation of the Hyaluronic Acid long linear chains in portions of a well definite size, comprised between 28 and 40 monomers, guarantees a massive stimulation of the CD 44 receptors, resulting in an intense reticular collagen production.

HYALURONANS 2.0



WHY IS SISTHAEMA HEVO *T* DIFFERENT?

- SISTHAEMA HEVO *T* differentiates from all traditional bio-revitalizing and bio-stimulating products commonly used for its **real dermal regeneration effect.**

- The superiority of SISTHAEMA HEVO *T* is also clear when compared to products containing polylactic acid or other similar substances: these products stimulate CD 39 & CD 40 receptors, therefore mainly increasing the fibrotic collagen type I production.
- SISTHAEMA HEVO *T*, on the other hand, is able to stimulate CD 44 receptors, allowing the synthesis of reticular young collagen type III.



A NEW
THERAPEUTIC
APPROACH

A NEW THERAPEUTIC APPROACH



SISTHAEMA HEVO T is a unique product, introducing a new distinctive therapeutic approach:
The Systemic Dermal Regeneration.

THE SYSTEMIC DERMAL REGENERATION



THE SYSTEMIC DERMAL REGENERATION


DERMAL REGENERATION

The aesthetic effect of the **Systemic Dermal Regeneration** is visible right after the first treatment, with a powerful, moisturizing and tensive effect.

- The real regenerating action will show its effects after a few weeks;
- Regeneration continues and lasts for weeks after the injection;
- Remarkable improvements, visible at the histological level, are noticeable after the first treatment with **SISTHAEMA HEVO T** injections.



◦ Some hours after the infiltration using **SISTHAEMA HEVO T**



◦ Weeks after the infiltration using **SISTHAEMA HEVO T**




THE SYSTEMIC DERMAL REGENERATION

DERMAL REGENERATION

APPLICATION PROTOCOL



Such a specific product structure requires a clearly **Defined Implantation Technique.**



Subcutaneous injections, connective tissue, at a depth of 2.5-3.0 mm, using a Linear Retrograde Technique, with the release of around 0.1 ml of gel for each injection.

THE SYSTEMIC DERMAL REGENERATION


DERMAL REGENERATION

APPLICATION PROTOCOL

On average, depending on the skin condition and degree of photo/chrono aging, the patient will need three treatments with 2- or 3-week intervals between them for ideal results.

Subsequent recalls should be 60 days after the last treatment.

It is advisable to repeat this Application Protocol every year.



- 1 1st Treatment
- 2 2nd Treatment
- 3 3rd Treatment
- 4 1st Recall (One Single Treatment)
- 5 2nd Recall (One Single Treatment)
- 6 3rd Recall (One Single Treatment)
- 7 4th Recall (One Single Treatment)

TENSE TECHNIQUE

THE SYSTEMIC DERMAL REGENERATION

TENSE TECHNIQUE

- TENSE is a new injection procedure, exclusively developed for SISTHAEMA HEVO *T*;
- The Tense Technique was born thanks to the collaboration between important Universities and qualified international opinion leaders;

- The Tense Technique magnifies the SISTHAEMA HEVO *T* peculiarities, enhancing the efficacy of the product concerning the lifting and regenerative properties.


TENSE TECHNIQUE

TENSE TECHNIQUE

APPLICATION PROTOCOL

The areas to be treated are the following:

- 1 *Zygomatic Process*
- 2 *Zygomatic Bone*
- 3 *Mandibular Angle*
- 4 *Nasolabial Folds*
- 5 *Marionette's Wrinkles*
- 6 *Chin Area*



- Areas 1, 4, 5 and 6 should be approached with a single injection each;
- Area 2 can be approached with two distinctive injections or with the fan technique;
- Area 3 can similarly be treated with three distinctive injections or with the fan technique;
- At the end of the treatment, a light massage could be carried out to facilitate a more homogeneous placement of SISTHAEMA HEVO T in the whole malar area.

This Technique should be applied following the same protocol and time intervals as previously shown for standard techniques.

ANALYTICAL SPECIFICATION

SISTHAEMA

HEVO
T

Tests / Characteristics	Tolerance Limits	Test Method
Identification	Complies	Eur. Ph. Monograph 2011: 1472
Assay for Trehalose	10 mg/ml	Eur. Ph. Monograph 2011: 1472
Assay for Sodium Hyaluronate	25.0 mg/ml	Eur. Ph. Monograph 2011: 1472
Molecular Weight Sodium Hyaluronate	1.5 MDa	Eur. Ph. Monograph 2011: 1472
Intrinsic Viscosity	2.4 - 3.3 m ³ /kg	Eur. Ph. Monograph 2011: 1472 - 188 Q&Q
Appearance of Solution	Clear Abs ₆₀₀ ≤ 0.01	Eur. Ph. Monograph 2011: 1472
pH	6.8 - 7.6	Eur. Ph. Monograph 2011: 1472
Sterility	Sterile	Eur. Ph. 2.6.1
Endotoxins Test	Not more than 0.5 EU/ml	Eur. Ph. 2.6.14 Method D

One 2 ml syringe contains:

- Non cross-linked Hyaluronic Acid 50 mg
- Trehalose 20 mg

THE FOUNDATION OF SISTHAEMA HEVO ^T 1/2



Esterified Trehalose Analogues Protect Mammalian Cells from Heat Shock.
Bragg JT et al. Chembiochem. (2017)

Genetics of trehalose biosynthesis in desert-derived *Aureobasidium melanogenum* and role of trehalose in the adaptation of the yeast to extreme environments.
Jiang H et al. Curr Genet. (2018)

Impact of trehalose on the activity of sodium and potassium chloride in aqueous solutions: Why trehalose is worth its salt.
Poplinger M et al. Food Chem. (2017)

Trehalose: is it a potential inhibitor of antithrombin polymerization?
Martínez-Martínez I.
Biosci Rep. 2019 May 30. pii: BSR20190567. doi: 10.1042/BSR20190567. [Epub ahead of print]

Long-term nitrogen removal performance and kinetics of anaerobic ammonia oxidation bacteria (AnAOB) treating nitrogen-rich saline wastewater with trehalose addition.
Bai L, Li J, Li R, Wang J, Wang D.
Water Environ Res. 2019 May 29. doi: 10.1002/wer.1152.

Computational spectroscopy of trehalose, sucrose, maltose, and glucose: A comprehensive study of TDSS, NQR, NOE, and DRS.
Heid E, Honegger P, Braun D, Szabadi A, Stankovic T, Steinhäuser O, Schröder C.
J Chem Phys. 2019 May 7;150(17):175102. doi: 10.1063/1.5095058.

Mechanism of Trehalose-Induced Protein Stabilization from Neutron Scattering and Modeling.

Olsson C, Genheden S, García Sakai V, Swenson J.
J Phys Chem B. 2019 May 2;123(17):3679-3687. doi: 10.1021/acs.jpcc.9b01856. Epub 2019 Apr 18.

Hydrodynamic volume of trehalose and its water uptake mechanism.

Sakhaee N, Sakhaee S, Takallou A, Mobaraki A, Maddah M, Moshrefi R.
Biophys Chem. 2019 Jun;249:106145. doi: 10.1016/j.bpc.2019.03.002. Epub 2019 Apr 2.

Sugar metabolism as input signals and fuel for leaf senescence.

Kim J.
Genes Genomics. 2019 Mar 16. doi: 10.1007/s13258-019-00804-y. [Epub ahead of print] Review.

Protection against Dehydration: A Neutron Diffraction Study on Aqueous Solutions of a Model Peptide and Trehalose.

Di Gioacchino M, Bruni F, Ricci MA.
J Phys Chem B. 2018 Nov 15;122(45):10291-10295. doi: 10.1021/acs.jpcc.8b08046. Epub 2018 Nov 5.

BIBLIOGRAPHY

Effect of Hyaluronic Acid/Trehalose in Two Different Formulations on Signs and Symptoms in Patients with Moderate to Severe Dry Eye Disease.

Fondi K, Wozniak PA, Schmidl D, Bata AM, Witkowska KJ, Popa-Cherecheanu A, Schmetterer L, Garhöfer G.
J Ophthalmol. 2018 Aug 1;2018:4691417. doi: 10.1155/2018/4691417.
eCollection 2018.

Synergy between the small intrinsically disordered protein Hsp12 and trehalose sustain viability after severe desiccation.

Kim SX, Çamdere G, Hu X, Koshland D, Tapia H.
Elife. 2018 Jul 16;7. pii: e38337. doi: 10.7554/eLife.38337.

Trehalose improves human fibroblast deficits in a new CHIP-mutation related ataxia.

Casarejos MJ, Perucho J, López-Sendón JL, García de Yébenes J, Bettencourt C, Gómez A, Ruiz C, Heutink P, Rizzu P, Mena MA.
PLoS One. 2014 Sep 26;9(9):e106931. doi: 10.1371/journal.pone.0106931.
eCollection 2014.

Fibroblast heterogeneity in physiological conditions and fibrotic disease.

Casarejos MJ, Jelaska A., Strehlow D., Korn JH.
Springer Semin Immunopathol, 1999; 21(4): 385-05.

Quantification of type I and III collagen content in normal human skin in different age groups.

Rong YH, Zhang GA, Wang C. Ning FG.
Zhonghua Shao Shang Za Zhi, 2008; 24(1): 51-3

Connective tissue growth factor gene regulation. Requirements for its induction by transforming growth factor-beta 2 in fibroblasts.

Leask A, Holmes A, Black CM, Abraham DJ.
J. Biol. Chem., 2003; 278(15), 1300S-13. Epub 2003 Feb 5.

Hyaluronan affects protein and collagen synthesis by in vitro human skin fibroblasts.

Croce MA, Dyne K, Boraldi F, Quaglino D Jr, Cetta G, Tiozzo R, Pasquali ronchetti I, Tissue Cell, 2001; 33(4): 326-31.



THE SYSTEMIC
DERMAL REGENERATION



FROM SCIENCE
TO PERFORMANCE
THROUGH
CUTTING-EDGE
TECHNOLOGIES



NGH

NEXT GENERATION HYALURONICS